The financials
Vertex Pharmaceuticals by the numbers
Vertex Pharmaceuticals (VRTX) reported revenue of $3.33B in Q2 2026 (quarter ended June 30, 2026), up 12% from the same quarter a year earlier. That came with a gross margin of 85% and net income of $1.10B (33% of revenue). For the full year FY2025, revenue was $12.0B (+8.9% year on year) and net income $3.95B. Its largest product in 2026-Q1 was TRIKAFTAKAFTRIO at $2.35B, 79% of the disclosed total, just ahead of ALYFTREK at 14%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $3.33B | $2.96B | +12% |
| Gross profit | $2.84B | $2.56B | +11% |
| Operating income | $1.25B | $1.15B | +8.3% |
| Net income | $1.10B | $1.03B | +6.5% |
| Diluted EPS | $4.31 | $3.99 | +8.0% |
| Product | Revenue | Share |
|---|---|---|
| TRIKAFTAKAFTRIO | $2.35B | 79% |
| ALYFTREK | $424M | 14% |
| Manufactured Product Other | $136M | 4.5% |
| CASGEVY | $43M | 1.4% |
| JOURNAVX | $29M | 1.0% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $2.99B (-4.0%)
JOURNAVX grew +2131% year on yearCollaborative and Royalty -100% year on year
Segment Latestquarter on quarteryear on year
- TRIKAFTAKAFTRIO$2.35B$2.35BQoQ -11%year on year -7.1%-11%-7.1%
- ALYFTREK$424.4M$424.4MQoQ +72%year on year +687%+72%+687%
- Manufactured Product Other$135.9M$135.9MQoQ -23%year on year -12%-23%-12%
- CASGEVY$42.9M$42.9MQoQ +154%year on year +202%+154%+202%
- JOURNAVX$29.0M$29.0MQoQ +48%year on year +2131%+48%+2131%
- CASGEVY And JOURNAVX--QoQ -year on year ---
- Collaborative and Royalty$0.00$0.00QoQ -year on year -100%--100%